2021
DOI: 10.1016/j.ejphar.2021.174612
|View full text |Cite
|
Sign up to set email alerts
|

Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 43 publications
0
1
0
Order By: Relevance
“…PI3K/Akt/mTOR signaling pathway activation promotes tumorigenesis of cervical carcinoma, thus inhibiting this pathway may be a strategy for targeting therapies [19]. Furthermore, a recent study shows that HeLa cell line was more sensitive to Dactolisib compared to other key pathway inhibitors, suggesting that this PI3K/mTOR inhibitor therapy may be a potential benefit to cervical cancer patient [20].…”
Section: Introductionmentioning
confidence: 99%
“…PI3K/Akt/mTOR signaling pathway activation promotes tumorigenesis of cervical carcinoma, thus inhibiting this pathway may be a strategy for targeting therapies [19]. Furthermore, a recent study shows that HeLa cell line was more sensitive to Dactolisib compared to other key pathway inhibitors, suggesting that this PI3K/mTOR inhibitor therapy may be a potential benefit to cervical cancer patient [20].…”
Section: Introductionmentioning
confidence: 99%